Parallel evolution of circulating FABP4 and NT-proBNP in heart failure patients

Cardiovascular Diabetology

Volumn 12, Issue 1, 2013, Pages

  Cabré, Anna ^a,b   Valdovinos, Pilar ^b,c   Lázaro, Iolanda ^a,b   Bonet, Gil ^b,c   Bardají, Alfredo ^b,c   Masana, Lluís ^a,b  

^a INSTITUTO DE SALUD CARLOS III   (Spain)

^b INSTITUT D INVESTIGACIÓ SANITÀRIA PERE VIRGILI IISPV   (Spain)

^c HOSPITAL UNIVERSITARI JOAN XXIII   (Spain)

Author keywords

Diabetes; FABP4; Heart failure; NT proBNP; Obesity

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; FATTY ACID BINDING PROTEIN 4; BIOLOGICAL MARKER; BRAIN NATRIURETIC PEPTIDE; FABP4 PROTEIN, HUMAN; FATTY ACID BINDING PROTEIN; PEPTIDE FRAGMENT; PRO-BRAIN NATRIURETIC PEPTIDE (1-76);

ADULT; AGED; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL ASSESSMENT; DIABETIC PATIENT; FEMALE; FOLLOW UP; FUNCTIONAL ASSESSMENT; HEART FAILURE; HUMAN; MAJOR CLINICAL STUDY; MALE; PROSPECTIVE STUDY; WALKING SPEED; BLOOD; CASE CONTROL STUDY; CROSS-SECTIONAL STUDY; DISEASE COURSE; LONGITUDINAL STUDY; MIDDLE AGED;

AGED; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; CROSS-SECTIONAL STUDIES; DISEASE PROGRESSION; FATTY ACID-BINDING PROTEINS; FEMALE; HEART FAILURE; HUMANS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; NATRIURETIC PEPTIDE, BRAIN; PEPTIDE FRAGMENTS; PROSPECTIVE STUDIES;

EID: 84876951711     PISSN: None     EISSN: 14752840     Source Type: Journal    
DOI: 10.1186/1475-2840-12-72     Document Type: Article

References (35)

1. Velagaleti RS, Pencina MJ, Murabito JM, Wang TJ, Parikh NI, D'Agostino RB, Levy D, Kannel WB, Vasan RS. Long-term trends in the incidence of heart failure after myocardial infarction. Circulation 2008, 118:2057-2062. 10.1161/CIRCULATIONAHA.108.784215, 2729712, 18955667.
2. Horwich TB, Fonarow GC. Glucose, obesity, metabolic syndrome, and diabetes relevance to incidence of heart failure. J Am Coll Cardiol 2010, 55:283-293. 10.1016/j.jacc.2009.07.029, 2834416, 20117431.
3. Roberts AW, Clark AL, Witte KK. Review article: Left ventricular dysfunction and heart failure in metabolic syndrome and diabetes without overt coronary artery disease-do we need to screen our patients?. Diab Vasc Dis Res 2009, 6:153-163. 10.1177/1479164109338774, 20368207.
4. Cohen-Solal A, Beauvais F, Logeart D. Heart failure and diabetes mellitus: epidemiology and management of an alarming association. J Card Fail 2008, 14:615-625. 10.1016/j.cardfail.2008.04.001, 18722328.
5. Clark AL, Fonarow GC, Horwich TB. Waist circumference, body mass index, and survival in systolic heart failure: the obesity paradox revisited. J Card Fail 2011, 17:374-380. 10.1016/j.cardfail.2011.01.009, 21549293.
6. Furuhashi M, Hotamisligil GS. Fatty acid-binding proteins: role in metabolic diseases and potential as drug targets. Nat Rev Drug Discov 2008, 7:489-503. 10.1038/nrd2589, 2821027, 18511927.
7. Scheja L, Makowski L, Uysal KT, Wiesbrock SM, Shimshek DR, Meyers DS, Morgan M, Parker RA, Hotamisligil GS. Altered insulin secretion associated with reduced lipolytic efficiency in aP2-/- mice. Diabetes 1999, 48:1987-1994. 10.2337/diabetes.48.10.1987, 10512363.
8. Hotamisligil GS, Johnson RS, Distel RJ, Ellis R, Papaioannou VE, Spiegelman BM. Uncoupling of obesity from insulin resistance through a targeted mutation in aP2, the adipocyte fatty acid binding protein. Science 1996, 274:1377-1379. 10.1126/science.274.5291.1377, 8910278.
9. Makowski L, Boord JB, Maeda K, Babaev VR, Uysal KT, Morgan MA, Parker RA, Suttles J, Fazio S, Hotamisligil GS, Linton MF. Lack of macrophage fatty-acid-binding protein aP2 protects mice deficient in apolipoprotein E against atherosclerosis. Nat Med 2001, 7:699-705. 10.1038/89076, 11385507.
10. Xu A, Wang Y, Xu JY, Stejskal D, Tam S, Zhang J, Wat NM, Wong WK, Lam KS. Adipocyte fatty acid-binding protein is a plasma biomarker closely associated with obesity and metabolic syndrome. Clin Chem 2006, 52:405-413. 10.1373/clinchem.2005.062463, 16423904.
11. Cabre A, Lazaro I, Girona J, Manzanares JM, Marimon F, Plana N, Heras M, Masana L. Fatty acid binding protein 4 is increased in metabolic syndrome and with thiazolidinedione treatment in diabetic patients. Atherosclerosis 2007, 195:e150-158. 10.1016/j.atherosclerosis.2007.04.045, 17553506.
12. Cabre A, Lazaro I, Girona J, Manzanares JM, Marimon F, Plana N, Heras M, Masana L. Plasma fatty acid binding protein 4 is associated with atherogenic dyslipidemia in diabetes. J Lipid Res 2008, 49:1746-1751. 10.1194/jlr.M800102-JLR200, 18421072.
13. Coll B, Cabre A, Alonso-Villaverde C, Lazaro I, Aragones G, Parra S, Girona J, Masana L. The fatty acid binding protein-4 (FABP4) is a strong biomarker of metabolic syndrome and lipodystrophy in HIV-infected patients. Atherosclerosis 2008, 199:147-153. 10.1016/j.atherosclerosis.2007.09.032, 17983623.
14. Lazaro I, Diaz M, Cabre A, Masana L, Ibanez L. Fatty acid-binding protein-4 plasma levels are associated to metabolic abnormalities and response to therapy in girls and young women with androgen excess. Gynecol Endocrinol 2011, 27:935-939. 10.3109/09513590.2011.569608, 21605000.
15. Tso AW, Xu A, Sham PC, Wat NM, Wang Y, Fong CH, Cheung BM, Janus ED, Lam KS. Serum adipocyte fatty acid binding protein as a new biomarker predicting the development of type 2 diabetes: a 10-year prospective study in a Chinese cohort. Diabetes Care 2007, 30:2667-2672. 10.2337/dc07-0413, 17620449.
16. Xu A, Tso AW, Cheung BM, Wang Y, Wat NM, Fong CH, Yeung DC, Janus ED, Sham PC, Lam KS. Circulating adipocyte-fatty acid binding protein levels predict the development of the metabolic syndrome: a 5-year prospective study. Circulation 2007, 115:1537-1543. 10.1161/CIRCULATIONAHA.106.647503, 17389279.
17. Miyoshi T, Onoue G, Hirohata A, Hirohata S, Usui S, Hina K, Kawamura H, Doi M, Kusano KF, Kusachi S, Ninomiya Y. Serum adipocyte fatty acid-binding protein is independently associated with coronary atherosclerotic burden measured by intravascular ultrasound. Atherosclerosis 2010, 211:164-169. 10.1016/j.atherosclerosis.2010.01.032, 20193950.
18. von Eynatten M, Breitling LP, Roos M, Baumann M, Rothenbacher D, Brenner H. Circulating adipocyte fatty acid-binding protein levels and cardiovascular morbidity and mortality in patients with coronary heart disease. A 10-year prospective study. Arterioscler Thromb Vasc Biol 2012, 32:2327-2335. 10.1161/ATVBAHA.112.248609, 22679309.
19. Iwamoto M, Miyoshi T, Doi M, Takeda K, Kajiya M, Nosaka K, Nakayama R, Hirohata S, Usui S, Kusachi S, Sakane K, Nakamura K, Ito H. Elevated serum adipocyte fatty acid-binding protein concentrations are independently associated with renal dysfunction in patients with stable angina pectoris. Cardiovasc Diabetol 2012, 11:26. 10.1186/1475-2840-11-26, 3353231, 22433902.
20. Aragones G, Ferre R, Lazaro I, Cabre A, Plana N, Merino J, Heras M, Girona J, Masana L. Fatty acid-binding protein 4 is associated with endothelial dysfunction in patients with type 2 diabetes. Atherosclerosis 2010, 213:329-331. 10.1016/j.atherosclerosis.2010.07.026, 20723896.
21. Aragonès G, Saavedra P, Heras M, Cabré A, Girona J, Masana L. Fatty acid-binding protein 4 impairs the insulin-dependent nitric oxide pathway in vascular endothelial cells. Cardiovasc Diabetol 2012, 11:72. 10.1186/1475-2840-11-72, 3503556, 22709426.
22. Lamounier-Zepter V, Look C, Alvarez J, Christ T, Ravens U, Schunck WH, Ehrhart-Bornstein M, Bornstein SR, Morano I. Adipocyte fatty acid-binding protein suppresses cardiomyocyte contraction: a new link between obesity and heart disease. Circ Res 2009, 105:326-334. 10.1161/CIRCRESAHA.109.200501, 19608978.
23. Dickstein K, Cohen-Solal A, Filippatos G, McMurray JJ, Ponikowski P, Poole-Wilson PA, Strömberg A, van Veldhuisen DJ, Atar D, Hoes AW, Keren A, Mebazaa A, Nieminen M, Priori SG, Swedberg K, . ESC Committee for Practice Guidelines (CPG) ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur Heart J 2008, 29:2388-23442. ESC Committee for Practice Guidelines (CPG).
24. Lang RM, Bierig M, Devereux RB, Flachskampf FA, Foster E, Pellikka PA, Picard MH, Roman MJ, Seward J, Shanewise JS, Solomon SD, Spencer KT, Sutton MS, Stewart WJ. Recommendations for chamber quantification: a report from the American Society of Echocardiography's Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology. J Am Soc Echocardiogr 2005, 18:1440-1463. 10.1016/j.echo.2005.10.005, 16376782.
25. Rodeheffer RJRM Congestive heart failure: diagnosis, evaluation, and surgical therapy. Murphy JG 2000, 55-74. Mayo Clin Cardiol R, Rodeheffer RJRM.
26. Hulsmann M, Berger R, Sturm B, Bojic A, Woloszczuk W, Bergler-Klein J, Pacher R. Prediction of outcome by neurohumoral activation, the six-minute walk test and the Minnesota Living with Heart Failure Questionnaire in an outpatient cohort with congestive heart failure. Eur Heart J 2002, 23:886-891. 10.1053/euhj.2001.3115, 12042010.
27. Kubo SH, Schulman S, Starling RC, Jessup M, Wentworth D, Burkhoff D. Development and validation of a patient questionnaire to determine New York Heart Association classification. J Card Fail 2004, 10:228-235. 10.1016/j.cardfail.2003.10.005, 15190533.
28. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 1999, 130:461-470. 10.7326/0003-4819-130-6-199903160-00002, 10075613.
29. Bao Y, Lu Z, Zhou M, Li H, Wang Y, Gao M, Wei M, Jia W. Serum levels of adipocyte fatty acid-binding protein are associated with the severity of coronary artery disease in chinese women. PLoS One 2011, 6:e19115. 10.1371/journal.pone.0019115, 3084261, 21552513.
30. Liu M, Zhou M, Bao Y, Xu Z, Li H, Zhang H, Zhu W, Zhang J, Xu A, Wei M, Jia W. Circulating adipocyte fatty acid-binding protein levels are independently associated with heart failure. Clin Sci 2013, 124:115-122. 10.1042/CS20120004, 23013043.
31. Djoussé L, Bartz TM, Ix JH, Kochar J, Kizer JR, Gottdiener JS, Tracy RP, Mozaffarian D, Siscovick DS, Mukamal KJ, Zieman SJ. Fatty acid-binding protein 4 and incident heart failure: the Cardiovascular Health Study. Eur J Heart Fail 2013, 4:394-399.
32. Olsson LG, Swedberg K, Cleland JG, Spark PA, Komajda M, Metra M, Torp-Pedersen C, Remme WJ, Scherhag A, Poole-Wilson P. Prognostic importance of plasma NT-pro BNP in chronic heart failure in patients treated with a beta-blocker: results from the Carvedilol Or Metoprolol European Trial (COMET) trial. Eur J Heart Fail 2007, 9:795-801. 10.1016/j.ejheart.2007.07.010, 17693380.
33. Lainchbury JG, Troughton RW, Strangman KM, Frampton CM, Pilbrow A, Yandle TG, Hamid AK, Nicholls MG, Richards AM. N-terminal pro-B-type natriuretic peptide-guided treatment for chronic heart failure: results from the BATTLESCARRED (NT-proBNP-Assisted Treatment To Lessen Serial Cardiac Readmissions and Death) trial. J Am Coll Cardiol 2010, 55:53-60.
34. Bettencourt P, Azevedo A, Pimenta J, Friões F, Ferreira S, Ferreira A. N-terminal-pro-brain natriuretic peptide predicts outcome after hospital discharge in heart failure patients. Circulation 2004, 110:2168-2174. 10.1161/01.CIR.0000144310.04433.BE, 15451800.
35. Cabre A, Lazaro I, Girona J, Manzanares JM, Marimon F, Plana N, Heras M, Masana L. Plasma fatty acid-binding protein 4 increases with renal dysfunction in type 2 diabetic patients without microalbuminuria. Clin Chem 2008, 54:181-187.